• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Treace Medical Concepts Inc.

    5/15/25 4:30:03 PM ET
    $TMCI
    Medical/Dental Instruments
    Health Care
    Get the next $TMCI alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    TREACE MEDICAL CONCEPTS, INC.

    (Name of Issuer)


    Common stock, $0.001 par value

    (Title of Class of Securities)


    89455T109

    (CUSIP Number)


    05/09/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    89455T109


    1Names of Reporting Persons

    Gagnon Securities LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,402,470.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,709,970.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,709,970.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.3 %
    12Type of Reporting Person (See Instructions)

    BD, IA


    SCHEDULE 13G

    CUSIP No.
    89455T109


    1Names of Reporting Persons

    Gagnon Advisors, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    830,270.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    830,270.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    830,270.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.3 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    89455T109


    1Names of Reporting Persons

    Neil Gagnon
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    271,661.00
    6Shared Voting Power

    3,385,067.00
    7Sole Dispositive Power

    271,661.00
    8Shared Dispositive Power

    3,707,793.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,979,454.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.3 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    TREACE MEDICAL CONCEPTS, INC.
    (b)Address of issuer's principal executive offices:

    100 PALMETTO PARK PLACE, PONTE VEDRA, FL, 32081
    Item 2. 
    (a)Name of person filing:

    Neil Gagnon has sole voting and dispositive power over 271,661 shares of the Issuer's Common stock, $0.001 par value (the "Common Stock"). In addition, Mr. Gagnon has shared voting power over 3,385,067 shares of Common Stock and shared dispositive power over 3,707,793 shares of Common Stock. Mr. Gagnon is the managing member and principal owner of Gagnon Securities LLC ("GS"), an investment adviser registered with the U.S. Securities and Exchange Commission ("SEC") under the Investment Advisers Act of 1940, as amended (the "Advisers Act"), and a registered broker-dealer, in its role as investment manager to several customer accounts, foundations, partnerships and trusts (collectively, the "Accounts") to which it furnishes investment advice. GS and Mr. Gagnon may be deemed to share voting power with respect to 2,402,470 shares of Common Stock held in the Accounts and dispositive power with respect to 2,709,970 shares of Common Stock held in the Accounts. GS and Mr. Gagnon expressly disclaim beneficial ownership of all securities held in the Accounts. Mr. Gagnon is also the Chief Executive Officer of Gagnon Advisors, LLC ("Gagnon Advisors"), an investment adviser registered with the SEC under the Advisers Act. Mr. Gagnon and Gagnon Advisors, in its role as investment manager to Gagnon Investment Associates, LLC ("GIA"), a private investment fund, may be deemed to share voting and dispositive power with respect to the 830,270 shares of Common Stock held by GIA. Gagnon Advisors and Mr. Gagnon expressly disclaim beneficial ownership of all securities held by GIA.
    (b)Address or principal business office or, if none, residence:

    1370 Ave. of Americas, 26th Floor, New York, NY 10019
    (c)Citizenship:

    Gagnon Securities LLC Delaware limited liability company Gagnon Advisors, LLC Delaware limited liability company Neil Gagnon USA
    (d)Title of class of securities:

    Common stock, $0.001 par value
    (e)CUSIP No.:

    89455T109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Gagnon Securities LLC 2,709,970 Gagnon Advisors, LLC 830,270 Neil Gagnon 3,979,454
    (b)Percent of class:

    Gagnon Securities LLC 4.3% Gagnon Advisors, LLC 1.3% Neil Gagnon 6.3% Calculation of percentage of beneficial ownership is based on 62,904,952 Common Stock outstanding as of April 30, 2025, based on the Issuer's Form 10-Q filed with the Securities and Exchange Commission on May 8, 2025.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Gagnon Securities LLC 0 Gagnon Advisors, LLC 0 Neil Gagnon 271,661

     (ii) Shared power to vote or to direct the vote:

    Gagnon Securities LLC 2,402,470 Gagnon Advisors, LLC 830,270 Neil Gagnon 3,385,067

     (iii) Sole power to dispose or to direct the disposition of:

    Gagnon Securities LLC 0 Gagnon Advisors, LLC 0 Neil Gagnon 271,661

     (iv) Shared power to dispose or to direct the disposition of:

    Gagnon Securities LLC 2,709,970 Gagnon Advisors, LLC 830,270 Neil Gagnon 3,707,793

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Accounts described above in Item 2 have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, securities held in their respective accounts. To the knowledge of the Reporting Persons, the interest in any such account does not exceed 5% of the class of securities. Except to the extent described herein, the Reporting Person disclaims beneficial ownership of all such securities.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Gagnon Securities LLC
     
    Signature:/s/ Neil Gagnon
    Name/Title:Neil Gagnon/Managing Member
    Date:05/15/2025
     
    Gagnon Advisors, LLC
     
    Signature:/s/ Neil Gagnon
    Name/Title:Neil Gagnon/Chief Executive Officer
    Date:05/15/2025
     
    Neil Gagnon
     
    Signature:/s/ Neil Gagnon
    Name/Title:Neil Gagnon
    Date:05/15/2025
    Get the next $TMCI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TMCI

    DatePrice TargetRatingAnalyst
    2/4/2025$16.00Neutral → Buy
    BTIG Research
    12/31/2024$14.50Buy
    Lake Street
    12/17/2024$8.00Neutral
    Analyst
    5/16/2024$16.00 → $6.50Buy → Neutral
    UBS
    5/8/2024$15.00 → $5.50Overweight → Equal-Weight
    Morgan Stanley
    5/8/2024$17.00 → $7.00Buy → Hold
    Truist
    5/8/2024$15.00 → $6.00Buy → Hold
    Stifel
    5/8/2024$15.00 → $8.00Overweight → Neutral
    JP Morgan
    More analyst ratings

    $TMCI
    SEC Filings

    See more
    • Treace Medical Concepts Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)

      5/21/25 4:30:09 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • SEC Form SCHEDULE 13G filed by Treace Medical Concepts Inc.

      SCHEDULE 13G - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

      5/15/25 4:30:03 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Treace Medical Concepts Inc.

      SCHEDULE 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

      5/15/25 3:19:09 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care

    $TMCI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Jain Deepti was granted 23,917 shares, increasing direct ownership by 52% to 70,243 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      5/21/25 5:30:14 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Director Mott Richard W was granted 23,917 shares, increasing direct ownership by 2% to 1,096,861 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      5/21/25 5:30:05 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Director Hanna Betsy was granted 23,917 shares, increasing direct ownership by 112% to 45,243 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      5/21/25 5:30:07 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care

    $TMCI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Treace Medical Concepts upgraded by BTIG Research with a new price target

      BTIG Research upgraded Treace Medical Concepts from Neutral to Buy and set a new price target of $16.00

      2/4/25 7:10:07 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Lake Street initiated coverage on Treace Medical Concepts with a new price target

      Lake Street initiated coverage of Treace Medical Concepts with a rating of Buy and set a new price target of $14.50

      12/31/24 7:48:21 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Analyst resumed coverage on Treace Medical Concepts with a new price target

      Analyst resumed coverage of Treace Medical Concepts with a rating of Neutral and set a new price target of $8.00

      12/17/24 8:22:27 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care

    $TMCI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Treace John T. bought $524,064 worth of shares (60,000 units at $8.73), increasing direct ownership by 0.89% to 6,796,190 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      3/4/25 6:30:03 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Treace John T. bought $265,630 worth of shares (50,000 units at $5.31), increasing direct ownership by 0.77% to 6,523,095 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      9/17/24 5:17:19 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Director Treace James T bought $501,035 worth of shares (84,000 units at $5.96), increasing direct ownership by 7% to 1,223,441 units (SEC Form 4)

      4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)

      8/19/24 9:00:08 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care

    $TMCI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Treace Files Patent Infringement Suit Against Zimmer Biomet to Protect Lapiplasty® Bunion Technology

      PONTE VEDRA, Fla., June 05, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® procedures, today announced that it filed a lawsuit against Zimmer Biomet Holdings, Inc. and Paragon 28, Inc. (collectively, "Zimmer") (NYSE:ZBH), alleging infringement of 4 patents related to Treace's innovative Lapiplasty® 3D Bunion Correction® technologies. The suit was filed in the United States District Court for the District of Delaware, and seeks injunctive relief and damages. "Treac

      6/5/25 1:00:00 PM ET
      $TMCI
      $ZBH
      Medical/Dental Instruments
      Health Care
      Industrial Specialties
    • Treace Medical Concepts Reports First Quarter 2025 Financial Results

      PONTE VEDRA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Generated revenue of $52.6 million in first quarter 2025 representing growth of 3% over the same period in 2024.Improved first quarter 2025 net loss by 15% to $(15.9) million compared to $(18.7) million in the same period in 2024. Improved adjusted EBITDA by 53% to $(3.8) million in th

      5/8/25 4:05:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace to Report First Quarter 2025 Financial Results on May 8, 2025

      PONTE VEDRA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the first quarter 2025 after the close of trading on Thursday, May 8, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers an

      4/24/25 4:05:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care

    $TMCI
    Leadership Updates

    Live Leadership Updates

    See more
    • Treace Appoints Guy Guglielmino as Chief Commercial Officer

      PONTE VEDRA, Fla., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that Guy Guglielmino joined the Company as Chief Commercial Officer. In this new position, Mr. Guglielmino will lead Treace's commercial efforts and play a pivotal role in driving the Company's next phase of rapid innovation, strategic product commercialization, and growth. "I am thrilled to welcome Guy to the Treace team," said John T. Treace, CEO, Founder and B

      12/2/24 4:15:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace Medical Concepts Appoints Nathan Minnich as Senior Vice President, Marketing

      PONTE VEDRA, Fla., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced Nathan Minnich has been appointed Sr. Vice President, Marketing, effective immediately. In this new position, Mr. Minnich will lead all aspects of Treace's marketing efforts, with a focus on expanding the Company's physician outreach, patient awareness and market penetration efforts.  "I am delighted to welcome Nathan to the Treace team," said John T. Treace, CEO, Fou

      8/21/23 7:00:00 AM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace Appoints Julie Dewey as Chief Communications and Investor Relations Officer

      PONTE VEDRA, Fla., July 12, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today announced that Julie Dewey will join the Company as Chief Communications and Investor Relations Officer, effective July 17, 2023. In this new position, Ms. Dewey will lead all aspects of Treace's corporate communications and investor relations engagement, with a focus on expanding the company's outreach with the investment community and broadening the Company's relationships wit

      7/12/23 4:15:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care

    $TMCI
    Financials

    Live finance-specific insights

    See more
    • Treace Medical Concepts Reports First Quarter 2025 Financial Results

      PONTE VEDRA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Generated revenue of $52.6 million in first quarter 2025 representing growth of 3% over the same period in 2024.Improved first quarter 2025 net loss by 15% to $(15.9) million compared to $(18.7) million in the same period in 2024. Improved adjusted EBITDA by 53% to $(3.8) million in th

      5/8/25 4:05:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace to Report First Quarter 2025 Financial Results on May 8, 2025

      PONTE VEDRA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the first quarter 2025 after the close of trading on Thursday, May 8, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers an

      4/24/25 4:05:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Treace to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025

      PONTE VEDRA, Fla., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the fourth quarter and full year of 2024 after the close of trading on Thursday, February 27, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will rec

      2/6/25 4:15:00 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care

    $TMCI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Treace Medical Concepts Inc.

      SC 13G - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

      11/14/24 3:38:23 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Treace Medical Concepts Inc.

      SC 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

      11/12/24 6:01:03 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Treace Medical Concepts Inc.

      SC 13G - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)

      11/8/24 3:44:13 PM ET
      $TMCI
      Medical/Dental Instruments
      Health Care